Some years ago I owned shares in a small company that had developed software which let people with little or no programming skills develop their own business application software.

But their biggest roadblock was the attitude encountered from many potential clients: The software's claimed capabilities were seen as just "too good to be true", even after successful demonstrations.

Is Biocurex's RECAF bumping into this same wall from the professional medical or pharmaceutical establishments? Has Dr. Moro and company been forced to struggle against an entrenched Too-Good-to-be-True Syndrome?